Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-arm/Randomized, Double-blind, Active-controlled, Parallel-group Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR-1703 for Patients With EGPA

NCT05979051 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT05979051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05979051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-arm/Randomized, Double-blind, Active-controlled, Parallel-group Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR-1703 for Patients With EGPA
Lead sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 16, 2023
Completion date
December 31, 2028
Enrollment
166 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic granulomatosis with polyangiitis